Clinical Trials
268 trialsSurgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
BAYOU
AstraZeneca
ENVISION
UroGen Pharma Ltd.
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
SWOG Cancer Research Network
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
P3BC
Icahn School of Medicine at Mount Sinai
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
SunRISe-4
Janssen Research & Development, LLC
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
UNC Lineberger Comprehensive Cancer Center
Recovery Support for Bladder Cancer Patients and Caregivers
Northwell Health
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
NIAGARA
AstraZeneca
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
Brigham and Women's Hospital
CREST
Pfizer
HYBRID
Institute of Cancer Research, United Kingdom
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
PERTINENCE
Institut Cancerologie de l'Ouest
Medtronic Hugoâ„¢ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Dana-Farber Cancer Institute
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
GETUGV04
Institut du Cancer de Montpellier - Val d'Aurelle
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
CheckMate 7G8
Bristol-Myers Squibb
PRESERVE3
G1 Therapeutics, Inc.
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
National Institutes of Health Clinical Center (CC)
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Aprea Therapeutics
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
MasterKey-01
Black Diamond Therapeutics, Inc.
FORT-2
Bayer
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients
University of Kansas Medical Center
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Hoosier Cancer Research Network
IMvigor130
Hoffmann-La Roche